After-Hours Stock Movers 01/11: (BBBY) (ALLY) (DASH) Higher; (BIIB) (RC) (SI) Lower (more...)

Biogen's (BIIB) Aduhelm Access Will be Significantly Limited, Company's Future Rests on lecanemab Data - Analysts

Yesterday, on January 11th, 2022, CMS posted a draft NCD proposing to cover approved anti-amyloid antibodies for Alzheimer's Disease under CED (coverage with evidence development) and only a randomized controlled trials.

Biogen's (NASDAQ: BIIB) Aduhelm is currently the only FDA approved therapy for Alzheimer's Disease, and such strict coverage rules are expected to significantly limit access to the drug.

Mizuho analyst Salim Syed removes nearly all Aduhelm sales from his model, as he lowers the price target on... More

Biogen (BIIB) PT Lowered to $292 at Needham & Company

Needham & Company analyst Ami Fadia lowered the price target on Biogen (NASDAQ: BIIB) to $292.00 (from $328.00) while maintaining a Buy rating.

The analyst commented, "Following CMS's draft decision to cover monoclonal antibodies for treatment of Alzheimers disease under Coverage with Evidence... More

Ready Capital Corp. (RC) Prices Upsized 7M Share Offering at 15.56/sh

Ready Capital Corporation (NYSE: RC) today announced that the Company has priced an upsized underwritten public offering of 7,000,000 shares of common stock for total gross proceeds of approximately $108.9 million. In connection with the offering, the Company has granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of common stock. The Company intends to use the net proceeds from this offering to originate or acquire the Company's target assets consistent with its investment strategy and for general corporate purposes. The offering is expected to close on January 14, 2022, and is subject to customary closing... More